FDA Approves Motegrity (prucalopride) for Adults with Chronic Idiopathic Constipation (CIC)

Article Link: FDA Approves Motegrity (prucalopride) for Adults with Chronic Idiopathic Constipation (CIC)

Cambridge, Mass. – December 17, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) has announced that the U.S. Food and Drug Administration (FDA) has approved Motegrity™ (prucalopride), a once-daily, oral treatment option for adults with…

Source: FDA New Drug Approvals